logo Ibionextlogo Ibionext
  • HOME
  • ABOUT US
  • STRATEGY
  • TEAM
  • OUR COMPANIES
  • NEWS & MEDIA
  • CONTACT
  • Français
Twitter
LinkedIn

TILAK HEALTHCARE PUBLISHES ITS FIRST CLINICAL TRIAL, TIL-001

September 5, 2019Press releasesIbionext

A prospective study comparison of the mobile medical game, OdySight, with standard clinical eye tests

  • Study concludes that OdySight would be a good alternative for remote monitoring of vision between clinic visits, and could potentially assist in follow-up planning
September 05, 2019 07:00 AM Eastern Daylight Time

PARIS–TILAK HEALTHCARE, a unique mobile medical gaming start-up based in Paris, France and San Francisco, California, USA, is proud to announce the online publication of its first clinical trial results. The study, TIL-001, has been published in Ophthalmology and Therapy, a peer-reviewed, open access journal for ophthalmology.

OdySight is Tilak’s first mobile medical game for remote monitoring of patients with chronic eye diseases. The aim of this study was to compare the medical modules of OdySight with the gold standard tests for visual acuity, contrast sensitivity, and Amsler Grid. The results of this study demonstrate good agreement with statistical significance, for the measurements taken by two of OdySight’s medical modules (visual acuity and Amsler grid) when compared to the gold standards. OdySight would be a good alternative for remote monitoring of vision between clinic visits, and could potentially assist in follow-up planning.

Vinona Bhatia, MD MPH, Chief Medical Officer of Tilak Healthcare, comments: « More than 300,000 health apps are available worldwide, but few of these have claims based on strong clinical evidence. Physicians and patients need new, validated tools. OdySight is accessible on smartphones and tablets and challenges standard ophthalmic tools currently used in clinical practice. »

The study authors include: Tilak Healthcare’s co-founders, Professor José-Alain Sahel, Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine & Director of the UPMC Eye Center, and Dr. Jean-François Girmens, a retina expert at the Quinze-Vingts National Ophthalmology Hospital in Paris.

Read the full publication : https://link.springer.com/article/10.1007/s40123-019-0203-9

About Tilak Healthcare – https://www.tilakhealthcare.com/

Contacts

Tilak Healthcare
Edouard Gasser (CEO) – +33 (0) 7 62 27 18 42 – egasser@tilakhealthcare.com

Press – NewCap
Annie-Florence Loyer – +33 (0)1 44 71 00 12 / +33 (0)6 88 20 35 59 – afloyer@newcap.fr
Léa Jacquin – +33 (0)1 44 71 20 41 – ljacquin@newcap.fr

 

Previous post Chronolife, recently ISO 13 485 certified, receives CE mark approval for its Smart Textile solution and announces a strategic partnership Next post GrAI Matter Labs Reveals NeuronFlow Technology and Announces GrAIFlow SDK

SEARCH

ARCHIVES

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

CATEGORIES

  • Events (3)
  • News (78)
  • Press releases (84)

LATEST NEWS

  • Chronolife and Infiniwell join forces to deliver end-to-end remote health monitoring services March 22, 2023
  • Prophesee named in Best of MWC 2023 Awards by Android Authority February 28, 2023
  • Prophesee Announces Collaboration with Qualcomm to Optimize Neuromorphic Vision Technologies For the Next Generation of Smartphones, Unlocking a New Image Quality Paradigm for Photography and Video February 27, 2023
  • Prophesee named to La French Tech 120 February 20, 2023
  • Chronolife announces a strategic partnership with SAMI Advanced Electronics in Saudi Arabia February 14, 2023

CONTACT US

74, rue du Faubourg Saint-Antoine 75012 Paris
+33 1 76 21 47 50
contact@ibionext.com

LEGAL NOTICES

  • Cookies Policy
  • Privacy Policy
  • Terms of use
© 2023 iBionext. All rights reserved